The reason for bringing forward the publication of the interim report is to facilitate and speed up the process of determining if the reverse merger being evaluated is achievable.
For more information:
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, CFO and deputy CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at 09.15 CET on
This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail. Information in this press release is intended for investors.
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-brings-forward-the-publication-of-the-interim-report-for-q1-2024,c3964544
https://mb.cision.com/Main/9612/3964544/2745739.pdf
(c) 2024 Cision. All rights reserved., source